BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

854 related articles for article (PubMed ID: 12198643)

  • 21. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
    Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
    Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
    O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of cholestatic liver diseases; the role of ursodeoxycholic acid].
    Stiehl A
    Z Gastroenterol; 1992 Oct; 30(10):743-7. PubMed ID: 1441678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
    Lebensztejn DM
    Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
    Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
    J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis.
    Razori MV; Maidagan PM; Ciriaci N; Andermatten RB; Barosso IR; Martín PL; Basiglio CL; Sánchez Pozzi EJ; Ruiz ML; Roma MG
    Biochem Pharmacol; 2019 Oct; 168():48-56. PubMed ID: 31202734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathogenesis of cholestatic liver disease and therapeutic approaches.
    Hirschfield GM; Heathcote EJ; Gershwin ME
    Gastroenterology; 2010 Nov; 139(5):1481-96. PubMed ID: 20849855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
    Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
    Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid.
    Perez MJ; Macias RI; Duran C; Monte MJ; Gonzalez-Buitrago JM; Marin JJ
    J Hepatol; 2005 Aug; 43(2):324-32. PubMed ID: 15970352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ursodeoxycholic acid in the treatment of chronic liver disease.
    Cirillo NW; Zwas FR
    Am J Gastroenterol; 1994 Sep; 89(9):1447-52. PubMed ID: 8079918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Choleretic effects of ursodeoxycholic acid on experimentally-induced intrahepatic cholestasis.
    Mizoguchi Y; Miyajima K; Kioka K; Seki S; Kobayashi K; Morisawa S
    Osaka City Med J; 1989 Nov; 35(2):83-91. PubMed ID: 2628845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.
    Silveira MG; Lindor KD
    Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapy of cholestatic liver diseases.
    Paumgartner G
    J Dig Dis; 2010 Jun; 11(3):119-25. PubMed ID: 20579215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ursodeoxycholic acid therapy in hepatobiliary disease.
    Kowdley KV
    Am J Med; 2000 Apr; 108(6):481-6. PubMed ID: 10781781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of cholestatic liver diseases].
    Gatzen M; Pausch J
    Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
    Linares Rodríguez A
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
    [No Abstract]   [Full Text] [Related]  

  • 37. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
    Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress.
    Serviddio G; Pereda J; Pallardó FV; Carretero J; Borras C; Cutrin J; Vendemiale G; Poli G; Viña J; Sastre J
    Hepatology; 2004 Mar; 39(3):711-20. PubMed ID: 14999689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.
    Botla R; Spivey JR; Aguilar H; Bronk SF; Gores GJ
    J Pharmacol Exp Ther; 1995 Feb; 272(2):930-8. PubMed ID: 7853211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
    Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
    J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.